ImmunoGen

ImmunoGen Inc.
Public
Traded as NASDAQ: IMGN
Industry healthcare
Founded 1981
Headquarters Waltham, Massachusetts, United States
Number of employees
280
Website www.immunogen.com

ImmunoGen, Inc. (NASDAQ: IMGN) is a biotechnology company focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and is headquartered in Waltham, Massachusetts.[1]

An ImmunoGen ADC contains a manufactured antibody that binds to a target found on cancer cells, with one of the company's potent cell-killing agents attached as a "payload". The antibody serves to deliver the cell-killing agent specifically to cancer cells bearing its target and the payload serves to kill these cells. In some cases, the antibody also has anticancer activity.

Payload technology

The ADCs currently in the clinic with ImmunoGen technology employ one of the company's maytansinoid cell-killing agents, either DM1 or DM4, or one of the company's DNA-acting IGN payloads.

Collaborations & licensing

The company also selectively outlicenses limited use of its technology to other companies. Companies licensing ImmunoGen's technology include Amgen, Bayer HealthCare, Biotest, Genentech/Roche, Eli Lilly, Novartis, Sanofi, and Takeda.[4] Roche's Kadcyla (ado-trastuzumab emtansine) utilizes ImmunoGen's ADC technology. It has been approved and launched in a number of countries, including the US, where it is marketed by Genentech, a member of the Roche Group.[5][6] In October 2015, the company disclosed that Kadcyla had failed to meets its primary endpoint in the Phase II/III GATSBY trial investigating the second line treatment of HER2-positive advanced gastric cancer.[7]

Pipeline

ImmunoGen uses its ADC technology to develop its own product candidates. These include;[4]

References


This article is issued from Wikipedia - version of the 10/15/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.